Affinia Therapeutics Appoints Hideo Makimura, M.D., Ph.D. as Chief Medical Officer
Position
Chief Medical Officer
Company
Affinia Therapeutics
WalthamOtherBiotechnologyHealth CareresearchDescription
Affinia Therapeutics has appointed Hideo Makimura, MD, PhD as its Chief Medical Officer. Dr Makimura brings extensive leadership experience in early- and late-stage clinical research and development in the biopharmaceutical industry and academic research, as well as complementary clinical practice expertise as an endocrinologist. His appointment is a key step in progressing the lead investigational drug program, AFTX-201 in BAG3 dilated cardiomyopathy, toward an IND application later this year and building the pipeline of cardiovascular and neurologic programs.
Quick answer
Affinia Therapeutics Appoints Hideo Makimura, M.D., Ph.D. as Chief Medical Officer (February 5, 2025). Affinia Therapeutics is based in Waltham, Massachusetts, United States.
- Who is the new Chief Medical Officer at Affinia Therapeutics?
- Affinia Therapeutics named Hideo Makimura Chief Medical Officer, announced February 5, 2025.
- What did Affinia Therapeutics announce on February 5, 2025?
- Affinia Therapeutics has appointed Hideo Makimura, MD, PhD as its Chief Medical Officer. Dr Makimura brings extensive leadership experience in early- and late-stage clinical research and development in the biopharmaceutical industry and academic research, as well as complementary clinical practice expertise as an endocrinologist.
- What does Affinia Therapeutics do?
- Affinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases.
- Where is Affinia Therapeutics based?
- Affinia Therapeutics is based in Waltham, Massachusetts, United States.
- Which similar companies made leadership changes around the same time?
- Climb Bio, Inc. (February 25, 2025), QuantHealth (January 13, 2025), National MPS Society (February 5, 2025) and Autonomix Medical (February 6, 2025) also announced leadership changes within 45 days of Affinia Therapeutics.
Source: Fundz verified event record.
Other recent leadership changes in research and Biotechnology
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer (February 25, 2025)
- QuantHealth Appoints Sharon Dagan as Chief Architect and Siwar El Assad as Chief Information Security Officer (January 13, 2025)
- National MPS Society Appoints Dr. Scott Loiler as Chief Scientific Officer (February 5, 2025)
- Autonomix Medical Appoints Julie Manchester as VP Regulatory Affairs and Quality (February 6, 2025)
- Uvax Bio Appoints Kevin O'Neill as Interim Chief Executive Officer (CEO) (February 4, 2025)
- NGM Bio Appoints Dr. Wendy Yeh as Chief Medical Officer, Dr. Hsiao D. Lieu Steps Down (February 4, 2025)
Who to call at Affinia Therapeutics, and when
A new leader at Affinia Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Affinia Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Affinia Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Affinia Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Affinia Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Affinia Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.